Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu)

European Journal of Cancer

Volumn 43, Issue 3, 2007, Pages 481-489

  Reid, Alison ^a   Vidal, Laura ^a   Shaw, Heather ^a   de Bono, Johann ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Dual inhibition; EGFR; ErbB receptors; HER2; Lapatinib; Signal transduction

Indexed keywords

ANGIOGENESIS INHIBITOR; BIBW 2993; CANERTINIB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; GEFITINIB; HKI 272; LAPATINIB; MONOCLONAL ANTIBODY; PACLITAXEL; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLERGIC RASH; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; FATIGUE; GASTROINTESTINAL TOXICITY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; NAUSEA; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN FAMILY; RASH; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN TOXICITY; THROMBOCYTOPENIA; VOMITING;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I; GENES, ERBB-1; GENES, ERBB-2; HUMANS; NEOPLASMS; PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 33846566408     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.11.007     Document Type: Article

References (82)

1. Olayioye M.A., Neve R.M., Lane H.A., and Hynes N.E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19 13 (2000) 3159-3167
2. Baselga J., and Arteaga C.L. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23 11 (2005) 2445-2459
3. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 2 (2001) 127-137
4. Tzahar E., Waterman H., Chen X., et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16 10 (1996) 5276-5287
5. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
6. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235 4785 (1987) 177-182
7. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244 4905 (1989) 707-712
8. Toikkanen S., Helin H., Isola J., and Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10 7 (1992) 1044-1048
9. Paez J.G., Janne P.A., Lee J.C., et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304 5676 (2004) 1497-1500
10. Lynch T.J., Bell D.W., Sordella R., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl J Med 350 21 (2004) 2129-2139
11. Kalyankrishna S., and Grandis J.R. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24 17 (2006) 2666-2672
12. Heinrich M.C., Corless C.L., Demetri G.D., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21 23 (2003) 4342-4349
13. Britten C.D. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther 3 10 (2004) 1335-1342
14. Kokai Y., Myers J.N., Wada T., et al. Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts. Cell 58 2 (1989) 287-292
15. Alimandi M., Romano A., Curia M.C., et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10 9 (1995) 1813-1821
16. Motoyama A.B., Hynes N.E., and Lane H.A. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res 62 11 (2002) 3151-3158
17. Xia W., Lau Y.K., Zhang H.Z., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 12 (1999) 4164-4174
18. Tateishi M., Ishida T., Kohdono S., et al. Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. Surg Oncol 3 2 (1994) 109-113
19. Ye D., Mendelsohn J., and Fan Z. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225. Oncogene 18 3 (1999) 731-738
20. Worthylake R., Opresko L.K., and Wiley H.S. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem 274 13 (1999) 8865-8874
21. Finn RS, Wilson CA, Chen J, et al. Biologic effects of CP-724,714, a selective HER-2/neu kinase inhibitor, on human breast cancer cells with variable expression of EGFR and HER-2 AACR. Meeting Abstracts, Mar 2004;2004: 1052.
22. Moulder S.L., Yakes F.M., Muthuswamy S.K., et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61 24 (2001) 8887-8895
23. Moasser M.M., Basso A., Averbuch S.D., and Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61 19 (2001) 7184-7188
24. Normanno N., Campiglio M., De L.A., et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol 13 1 (2002) 65-72
25. Ye D., Mendelsohn J., and Fan Z. Androgen and epidermal growth factor down-regulate cyclin-dependent kinase inhibitor p27Kip1 and costimulate proliferation of MDA PCa 2a and MDA PCa 2b prostate cancer cells. Clin Cancer Res 5 8 (1999) 2171-2177
26. Ritter CA, Bianco R, al. DTe. HER2-overexpressing human breast cancer cells selected for Herceptin (trastuzumab) resistance in vivo retain HER2 gene amplification and overexpress HER1/EGF receptor ligands [abstract]. In: Proceedings of the AACR, vol. 44; 2003. p. R4869.
27. Konecny G.F.R., Venkatesan N., et al. The novel dual kinase inhibitor GW572016 is particularly active in HER2-positive and trastuzumab-conditioned breast cancer cells [abstract]. Breast Cancer Res Treat 82 (2003) S171
28. Goldstein N.I. Prewett M., Zuklys K., Rockwell P., and Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1 11 (1995) 1311-1318
29. Ciardiello F., De Vita F., Orditura M., Comunale D., and Galizia G. Cetuximab in the treatment of colorectal cancer. Future Oncol 1 2 (2005) 173-181
30. Cerea G., Ricotta R., Schiavetto I., et al. Cetuximab for treatment of metastatic colorectal cancer. Ann Oncol 17 Suppl. 7 (2006) vii66-vii67
31. Lilenbaum R.C. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res 12 14 Pt 2 (2006) 4432s-4435s
32. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23 34 (2005) 8646-8654
33. Nahta R., and Esteva F.J. Herceptin: mechanisms of action and resistance. Cancer Lett 232 2 (2006) 123-138
34. Morrison C., Zanagnolo V., Ramirez N., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24 15 (2006) 2376-2385
35. Mendelsohn J., and Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33 4 (2006) 369-385
36. Giaccone G. Targeting HER1/EGFR in cancer therapy: experience with erlotinib. Future Oncol 1 4 (2005) 449-460
37. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 22 (2005) 5235-5246
38. Britten C.D. Pegram M., Rosen P., et al. Targeting ErbB receptor interactions: a phase I trial of trastuzumab and erlotinib in metastatic HER2+ Breast Cancer. 2004 ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 22 July 15 Suppl. (2004) 3045
39. Patnaik A., Beeram M., de Bono J.S., et al. Phase I and pharmacokinetics (PK) of combined erbB1 and erbB2 blockade with OSI-774 (Erlotinib; E) and trastuzumab (T) in combination with weekly paclitaxel (P) in patients (pts) with advanced solid tumors. 2005 ASCO annual meeting proceedings. J Clin Oncol 23 16S Part I of II (June 1 Suppl.) (2005) 2000
40. Moulder S.L., and Arteaga C.L. A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2). Clin Breast Cancer 4 2 (2003) 142-145
41. Agus D.B., Akita R.W., Fox W.D., et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2 2 (2002) 127-137
42. Schaefer G., Fitzpatrick V.D., and Sliwkowski M.X. Gamma-heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175. Oncogene 15 12 (1997) 1385-1394
43. Mendoza N. Phillips G.L., Silva J., Schwall R., and Wickramasinghe D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res 62 19 (2002) 5485-5488
44. Takai N., Jain A., Kawamata N., et al. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth. Cancer 104 12 (2005) 2701-2708
45. Jackson J.G., St Clair P., Sliwkowski M.X., and Brattain M.G. Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64 7 (2004) 2601-2609
46. Agus D.B., Gordon M.S., Taylor C., et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23 11 (2005) 2534-2543
47. Malik M.A., Totpal K., Balter I., et al. Dose response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res 44 (2003) 150 [abstr 773]
48. Agus D.B., Sweeney C.J., Morris M., et al. Efficacy and safety of single agent pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in hormone refractory prostate cancer after failure of taxane-based therapy. 2005 ASCO annual meeting proceedings. J Clin Oncol 23 16S Part I of II (June 1 Suppl.) (2005) 4624
49. de Bono J.S., Bellmunt J., Droz J., et al. An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy nai{dotless}̈ve patients (pts) with Hormone Refractory Prostate Cancer (HRPC). 2005 ASCO annual meeting proceedings. J Clin Oncol 23 16S Part I of II (June 1 Suppl.) (2005) 4609
50. Gordon M.S., Matei D., Aghajanian C., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24 26 (2006) 4324-4332
51. Heymach J.V., Nilsson M., Blumenschein G. Papadimitrakopoulou V., and Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12 14 Pt 2 (2006) 4441s-4445s
52. Titus M.A., Schell M.J., Lih F.B., Tomer K.B., and Mohler J.L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11 13 (2005) 4653-4657
53. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 5 (2006) 2815-2825
54. Gregory C.W., He B., Johnson R.T., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 11 (2001) 4315-4319
55. Rusnak D.W., Lackey K., Affleck K., et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 1 2 (2001) 85-94
56. Rusnak D.W., Affleck K., Cockerill S.G., et al. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer. Cancer Res 61 19 (2001) 7196-7203
57. Xia W., Mullin R.J., Keith B.R., et al. Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 21 41 (2002) 6255-6263
58. Konecny G.E. Pegram M.D., Venkatesan N., et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66 3 (2006) 1630-1639
59. Burris H.A., Hurwitz H.I., Dees E.C., et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 23 23 (2005) 5305-5313
60. Versola M., Burris H.A., Jones S., et al. Clinical activity of GW572016 in EGF10003 in patients with solid tumors. 2004 ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 22 No. 14S (July 15 Suppl.) (2004) 3047
61. Minami H., Nakagawa K., Kawada K., et al. A phase I study of GW572016 in patients with solid tumors. 2004 ASCO annual meeting proceedings (post-meeting edition). J Clin Oncol 22 No. 14S (July 15 Suppl.) (2004) 3048
62. Storniolo A., Burris H. Pegram M., et al. A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen. 2005 ASCO annual meeting proceedings. J Clin Oncol 23 No. 16S Part I of II (June 1 Suppl.) (2005) 559
63. Blackwell K.L., Burstein H. Pegram M., et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. No. 16S Part I of II (June 1 Suppl.). J Clin Oncol 23 (2005) 3004
64. Gomez H.L., Chavez M.A., Doval D.C., et al. A phase II, randomized trial using the small molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer. No. 16S Part I of II (June 1 Suppl.). J Clin Oncol 23 (2005) 3046
65. Spector N.L., Blackwell K., and Hurley J. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 502
66. Lin N.U., Carey L.A., Liu M.C., et al. Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 503
67. .
68. Fields A.L., Rinaldi D.A., Henderson C.A., et al. An open-label multicenter phase ii study of oral lapatinib (gw572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. 2005 ASCO annual meeting proceedings. J Clin Oncol 23 No. 16S Part I of II (June 1 Suppl.) (2005) 3583
69. Abidoye O.O., Cohen E.E., Wong S.J., et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 5568
70. Ravaud A., Gardner J., Hawkins R., et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 4502
71. Lewis N., Marshall J., Amelsberg A., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 3091
72. Mom C.H., Eskens F.A., Gietema J.A., et al. Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule. 2006 ASCO annual meeting proceedings Part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 3025
73. Agus DB, Terlizzi E, Stopfer P, Amelsberg A, Gordon MS. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours. J Clin Oncol 2006;24(No. 18S (June 20 Suppl.)):2074. 2006 ASCO annual meeting proceedings part I.
74. Shaw H. Plummer R., Vidal L., et al. A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumours. 2006 ASCO annual meeting proceedings part I. J Clin Oncol 24 No. 18S (June 20 Suppl.) (2006) 3027
75. Tsou H.R., Overbeek-Klumpers E.G., Hallett W.A., et al. Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem 48 4 (2005) 1107-1131
76. Kwak E.L., Sordella R., Bell D.W., et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102 21 (2005) 7665-7670
77. Rabindran S.K. Antitumor activity of HER-2 inhibitors. Cancer Lett 227 1 (2005) 9-23
78. Rinehart JJ, Wilding G, Wilson I, et al. A phase I clinical and pharmacokinetic study of oral CI-1033, a pan-erbB tyrosine kinase inhibitor, in patients with advanced solid tumors. Proc Am Soc Clin Oncol 2002;(abstract 41).
79. Slichenmyer W.J., Elliott W.L., and Fry D.W. CI-1033, a pan-erbB tyrosine kinase inhibitor. Semin Oncol 28 5 Suppl. 16 (2001) 80-85
80. Campos S., Hamid O., Seiden M.V., et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol 23 24 (2005) 5597-5604
81. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?. Oncology (Williston Park) 17 11 Suppl. 12 (2003) 23-28
82. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough?. Clin Cancer Res 9 7 (2003) 2389-2390